

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1614

U.S. Appln. No. : 10/624,145 Confirmation No. : 5669 U.S. Filing Date : July 21, 2003) Examiner:	To be assigned
Title of Invention: 4-Hydroxy-2H-Thieno[2, Dioxides, Process for Pre Thereof	-	
Attny. Docket No.: 1/1375		
Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450		
December 15, 2003		
TRANSMITTAL LETTER FOR INFO	RMATION DISCL	OSURE STATEMENT
Sir:		
Transmitted herewith concerning the subject a Statement (Form 1449A/B) under 37 C.F.R. § hereinbelow.		
1.97(b). This Statement is being date of a national application other than a cont §1.53 (d); ii) within three (3) months of the da 37 C.F.R. §1.491 in an international application the merits; or iv) before the mailing of a fir continued examination under 37 C.F.R. §1.114	tinued prosecution a te of entry of the na- on; iii) before the ma est Office action afte	tional stage as set forth in illing of a first Office action
1.97(c). This Statement is being C.F.R. §1.97(b), but before the mailing date of notice of allowance under 37 C.F.R. §1.311, of in the application. This Statement is being account to the application.	f: i) a final action un or iii) an action that c	der 37 C.F.R. §1.113, ii) a
A statement as specified in 37	C.F.R. §1.97(e) [see	e below]; or
The fee set forth in 37 C.F.R. §	1.17(p).	

	The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
§1.97(c)	97(d). This Statement is being filed after the period specified in 37 C.F.R. but on or before payment of the issue fee. This Statement is accompanied by a tas specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.
	97(e).
c	Each item of information contained in the instant information disclosure attement was first cited in any communication from a foreign patent office in a punterpart foreign application not more than three (3) months prior to the filing of the instant information disclosure statement; or
f n ir §	No item of information contained in the instant information disclosure atement was cited in a communication from a foreign patent office in a counterpart oreign application, and, to the knowledge of the person signing this certification after aking reasonable inquiry, no item of information contained in the instant formation disclosure statement was known to any individual designated in 37 C.F.R 1.56(c) more than three (3) months prior to the filing of the instant information sclosure statement.
	The fee set forth in 37 C.F.R. §1.17(p).
	The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
disclosur counterp in sectio	704(d). Each item of information contained in the accompanying information e statement was cited in a communication from a foreign patent office in a art application, which communication was not received by any individual designated in 1.56(c) more than thirty (30) days prior to the filing of the accompanying on disclosure statement.

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted.

Mary-Filen M. Devlin Attorney for Applicant(s)

Reg. No. 27,928

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877 Tel: (203) 798-4866 Date: Certificate of Mailing

Mary-Ellen M. Devlin, Reg. No. 27,928

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner For Patents P. O. Box 1450 Alexandria, VA 22313-1450

on December 15, 200

3 of 3

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

1 8 2003

RADEWER

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known Application Number 10/624,145 Filing Date July 21, 2003 First Named Inventor G. Trummlitz Art Unit 1614 **Examiner Name** To be assigned

(Use as many sheets as necessary)

Attorney Docket Number | 1/1375

Examiner	Cite No.1	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials* No.	No.¹	Number-Kind Code ^{2 (# known)}	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		^{US-} 4,259,366 A	03/31/1981	W. Engel et al.	
		US-			
***************************************		US-	······································		
		US-			
		US-			-
		US-			
		US-			
***************************************		US-			
		US-			
·······		US-			
		US-			
		US-			

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	T ⁶		
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	IVIIVI-DD-1111	, , , , , , , , , , , , , , , , , , , ,	or Relevant Figures Appear			
	<u> </u>	WO 03/02503 A1	01/09/2003	Li, Jing				
					,			
·								
				,				

Examiner Date	
Signature Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

DEC 1 8 2003

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known				
		Application Number	10/624,145			
INFO	RMATION D	ISCLO	SURE	Filing Date	July 21, 2003	
STAT	STATEMENT BY APPLICANT		First Named Inventor	G. Trummlitz		
				Art Unit	1614	
	(Use as many sheets as necessary)		Examiner Name	To be assigned		
Sheet	2	of	2	Attorney Docket Number	1/1375	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
		Lazer, S. et al.: "Effect of Structural Modification of Enol-Carboxymide-Type Nonsteroidal Antiinflammatory Drugs on COX-2/COX-1 Selectivity" Journal of Medicinal Chemistry, American Chemical Society, Washington, US, vol. 40, 1997, pages 980-989, XP000974272, ISSN: 0022-2623, page 980, column 1, paragraph 1, Table 2		
			<u></u>	
	•••••			
	•••••			
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
Examiner		Date		

ſ		l l	1
Examiner		Date	1
Signature	•	Considered	1

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.